ArticleJapanese journal of cancer research : Gann2001
Hypoxia reduces hormone responsiveness of human breast cancer cells.
Article in Japanese journal of cancer research : Gann, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Pooled it
- Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer.Translational oncology · 2025Article
- Recent Advances in Carcinogenesis Transcription Factors: Biomarkers and Targeted Therapies.Cancers · 2023Article
- Serine starvation silences estrogen receptor signaling through histone hypoacetylation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- PET/MRI of hypoxia and vascular function in ER-positive breast cancer: correlations with immunohistochemistry.European radiology · 2023Article
- Acute vs. chronic vs. intermittent hypoxia in breast Cancer: a review on its application in in vitro research.Molecular biology reports · 2022Review
- Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer.Cancers · 2022Article
- The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- A worldwide map of swine short tandem repeats and their associations with evolutionary and environmental adaptations.Genetics, selection, evolution : GSE · 2021Article
- Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.Biomedicines · 2021Review
- Myocardial Expression of Estrogen Receptor-mRNA Is Associated With Lower Markers of Post-operative Organ Damage in Young Patients With Congenital Cardiac Defect.Frontiers in pediatrics · 2021Article
- Article
- How interacting pathways are regulated by miRNAs in breast cancer subtypes.BMC bioinformatics · 2016Article
- Associations of proteins relevant to MAPK signaling pathway (p38MAPK-1,HIF-1 and HO-1) with coronary lesion characteristics and prognosis of peri-menopausal women.Lipids in health and disease · 2016Article
- Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells.Oncology reports · 2015Article
- HIF-1α (1772C>T) polymorphism as marker for breast cancer development.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.Oncotarget · 2015Article
- Positron Emission Tomography in Breast Cancer.Diagnostics (Basel, Switzerland) · 2015Review
- Article
- Estrogen alleviates acetic acid-induced gastric or colonic damage via both ERα- and ERβ-mediated and direct antioxidant mechanisms in rats.Inflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to hormonal therapy frequently occurs following successful treatment in breast cancer. The mechanism responsible for this acquired resistance is still unknown. It has been suggested that a hypoxic tumor microenvironment promotes malignant progression of cancer, i.e., hypoxia may promote estrogen-independent growth (a more malignant phenotype) of breast cancer. To clarify this hypothesis, the effects of hypoxia on the growth responses to hormonal agents and the expression levels of estrogen receptor (ER)-alpha and progesterone receptor (PgR) were investigated in two human breast cancer cell lines, ML-20 and KPL-1. The expression level of ER-alpha was significantly decreased by hypoxia (1% O(2)) in a time-dependent manner in both cell lines. Hypoxia also significantly reduced the growth-promoting effect of estradiol (E2) and the growth-inhibitory effects of an antiestrogen, ICI 182 780, and a progestin, medroxyprogesterone acetate, in both cell lines. In addition, hypoxia markedly suppressed the induction of PgR mRNA and protein by E2 in both cell lines. To clarify further the effect of hypoxia on ER-alpha expression, the expression levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha), a marker of hypoxia and ER-alpha were immunohistochemically examined in 36 breast cancer specimens. ER-alpha expression (both its proportion and intensity) was significantly lower in nuclear HIF-1 alpha-positive tumors than in negative tumors. These findings indicate that hypoxia down-regulates ER-alpha expression as well as ER-alpha function in breast cancer cells. These processes may lead to an acquired resistance to hormonal therapy in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.